Matthew brings over two decades of experience in discovery research, pharma and biotechnology to Octant. His expertise includes immuno-oncology, autoimmunity, metabolic diseases and neuro-degeneration. Prior to joining Octant, he was Chief Translational Officer at Human Immunology Biosciences, served as SVP at insitro where he directed the Department of Translational Genetics and Biology, and was founder and Head of the Reverse Translation Organization at Genentech in the Cancer Immunology Department. His academic positions included Director of the Immunology Department at Institut Pasteur, Paris and co-founder of the Milieu Interieur Consortium, a global real-world data effort that has identified actionable insights into the genetic, microbiome and environmental determinants of health and disease.
Matthew's contributions have led to the discovery of new drug targets and he has helped to advance multiple drug candidates in first-in-human Ph1 studies and through post-marketing / indication expansion trials. His seminal work offered definitive evidence that naturally occurring tumor immunity in humans is established by the cross-priming of antigen-specific cytotoxic (CD8+) T cells, establishing the foundation for current approaches in immuno-oncology. He holds a Ph.D. in Immunology, an M.D. and residency training in Clinical Pathology, from Rockefeller University, Weill Cornell Medical School and New York Presbyterian Hospital, respectively.
Matthew enjoys spending quality time with his wife and daughter, as well as cycling, backcountry skiing and cooking.